|
Outcomes of patients following dose-dense neoadjuvant chemotherapy for muscle-invasive bladder cancer: Implications for organ-sparing strategies. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Astellas Pharma; Ferring; Ipsen; Janssen-Cilag |
Consulting or Advisory Role - Amgen; Ferring; Janssen-Cilag |
Travel, Accommodations, Expenses - Astellas Pharma; Bouchara Recordati; Ferring; Ipsen; Janssen; Pierre Fabre; Takeda |
|
|
Honoraria - Ipsen; Janssen |
Consulting or Advisory Role - Ipsen |
Travel, Accommodations, Expenses - Bouchara Recordati; Ipsen; Zambon |
|
|
No Relationships to Disclose |
|
|
Honoraria - Janssen; Roche |
Consulting or Advisory Role - Janssen; Roche |
Research Funding - Astellas Oncology; MSD |
Travel, Accommodations, Expenses - AstraZeneca; Roche |